10 August 2018
Visiongain has launched a new pharma report Global Asthma & COPD Therapies Market 2017-2027: Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs
The asthma & COPD market is maturing with generic competition looming for Advair, Symbicort, Spiriva and other leading drugs. However, novel drugs such as monoclonal antibodies for severe asthma and combination drugs are expected to drive growth in certain segments of the market. Phenotyping of asthma and COPD patient groups, telehealth and advances in inhaler design will also drive growth in 2016-2027.
The lead analyst of the report commented “For the overall asthma and COPD market, expansion into the BRIC and other emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth due to patent expiry, generic competition and low healthcare budgets.
The market benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups.”
Leading companies featured in the report include GSK, Boehringer Ingelheim, AstraZeneca, Novartis, Merck , Roche and Teva.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing demand for medical products in developing as well developed economies coupled with rising ageing population is expected to open new opportunities for medical device contract manufacturing industry over the forecast period.
01 December 2020
With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries.
01 December 2020
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.